Expertise in
5
conditions

Matthew G. Krebs

Alderley Park, 
Manchester, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Alderley Park, 
Manchester, ENG, GB 

Overview

Matthew Krebs practices practicing medicine in Manchester, United Kingdom.

Mr. Krebs is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ataxia-Telangiectasia, Telangiectasia, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 82 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Alderley Park, Manchester, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: May 27, 2026
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ladiratuzumab Vedotin
Study Phase: Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
Enrollment Status: Completed
Publish Date: November 29, 2023
Intervention Type: Drug
Study Drug: Afatinib
Study Phase: Phase 2
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

82 Total Publications

Current Insights and Future Directions of Multiomic and Spatial-Omic Analysis in Non-Small Cell Lung Cancer.
Current Insights and Future Directions of Multiomic and Spatial-Omic Analysis in Non-Small Cell Lung Cancer.
Journal: JCO precision oncology
Published: February 19, 2026

Frequently Asked Questions about Matthew G. Krebs

Is Matthew G. Krebs a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Matthew G. Krebs is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Matthew G. Krebs participate in research or clinical trials?

Yes. Matthew G. Krebs has published 82 articles and abstracts on conditions like Lung Cancer. You can view a list of Matthew G. Krebs's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Krebs's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile